Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
Antibody-dependent enhancement
Neutralizing antibodies
SARS-CoV-2
Therapies
Vaccines
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
30
04
2022
revised:
07
06
2022
accepted:
08
06
2022
pubmed:
27
6
2022
medline:
18
8
2022
entrez:
26
6
2022
Statut:
ppublish
Résumé
Antibody-dependent enhancement (ADE) is a complex phenomenon mediated by antibodies, frequently pre-existing non-neutralizing or sub-neutralizing antibodies. In the course of infectious diseases, ADE may be responsible for worsening the clinical course of the disease by increasing the virulence of pathogens (ADE of infection) or enhancing disease severity (ADE of disease). Here we reviewed the mechanisms thought to be behind the ADE phenomenon and its potential relationship with COVID-19 severity. Since the early COVID-19 epidemics, ADE has been mentioned as a possible mechanism involved in severe COVID-19 disease and, later, as a potential risk in the case of infection after vaccination. However, current data do not support its role in disease severity, both after infection and reinfection.
Identifiants
pubmed: 35753123
pii: S1567-5769(22)00427-1
doi: 10.1016/j.intimp.2022.108943
pmc: PMC9189100
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108943Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Microbiol Spectr. 2022 Apr 27;10(2):e0155321
pubmed: 35319248
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Biomed Pharmacother. 2020 Oct;130:110629
pubmed: 33406577
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Infect Immun. 2021 Mar 17;89(4):
pubmed: 33558319
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199
pubmed: 31296560
Antiviral Res. 2021 Nov;195:105185
pubmed: 34634289
Viruses. 2021 Dec 11;13(12):
pubmed: 34960752
Front Immunol. 2022 Jan 21;13:811952
pubmed: 35126396
Lancet Microbe. 2022 Jan;3(1):e62-e71
pubmed: 34723228
Cell Rep. 2022 May 31;39(9):110904
pubmed: 35617962
Front Immunol. 2021 Feb 24;12:640093
pubmed: 33717193
Immunol Rev. 2015 Nov;268(1):340-64
pubmed: 26497532
J Gen Virol. 1985 Sep;66 ( Pt 9):1969-82
pubmed: 4031825
PLoS Pathog. 2021 Sep 24;17(9):e1009958
pubmed: 34559854
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Sci Rep. 2022 Jul 23;12(1):12609
pubmed: 35871089
Virology. 1991 May;182(1):211-9
pubmed: 2024464
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Lancet Child Adolesc Health. 2022 Jun;6(6):384-392
pubmed: 35358491
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
mBio. 2021 Oct 26;12(5):e0198721
pubmed: 34579572
Int J Mol Sci. 2022 Feb 11;23(4):
pubmed: 35216104
Front Immunol. 2014 Sep 18;5:449
pubmed: 25278942
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Annu Rev Immunol. 2017 Apr 26;35:285-311
pubmed: 28446061
Biochim Biophys Acta Gen Subj. 2019 Oct;1863(10):1480-1497
pubmed: 31121217
Aust J Exp Biol Med Sci. 1964 Aug;42:465-82
pubmed: 14202187
Am J Prev Med. 2022 Jul;63(1):121-130
pubmed: 35410774
Transpl Infect Dis. 2022 Jun;24(3):e13827
pubmed: 35338554
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Sci Transl Med. 2022 Mar 9;14(635):eabm7853
pubmed: 35040666
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Nat Immunol. 2016 Sep;17(9):1102-8
pubmed: 27339099
Front Cell Infect Microbiol. 2020 Oct 02;10:580096
pubmed: 33123500
Sci Rep. 2021 Jun 14;11(1):12448
pubmed: 34127709
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
PLoS Pathog. 2021 Mar 22;17(3):e1009407
pubmed: 33750987
Int Immunopharmacol. 2021 Dec;101(Pt B):108187
pubmed: 34649114
J Acquir Immune Defic Syndr (1988). 1989;2(1):33-42
pubmed: 2465404
Sci Rep. 2021 Dec 9;11(1):23713
pubmed: 34887501
J Clin Virol. 2006 Feb;35(2):179-84
pubmed: 16112612
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Sci Adv. 2020 Feb 19;6(8):eaax0301
pubmed: 32128391
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
Vaccines (Basel). 2021 Nov 23;9(12):
pubmed: 34960121
Cell Rep. 2020 May 12;31(6):107642
pubmed: 32402275
iScience. 2022 Jan 21;25(1):103720
pubmed: 35005526
BMC Infect Dis. 2022 Jan 22;22(1):78
pubmed: 35065613
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
J Clin Pathol. 2021 Sep;74(9):614
pubmed: 32907911
Front Med (Lausanne). 2021 Oct 28;8:747190
pubmed: 34778310
PLoS One. 2012;7(4):e35421
pubmed: 22536382
J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):377-381
pubmed: 35413022
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
Int Immunopharmacol. 2021 Oct;99:108020
pubmed: 34426117
J Virol. 2003 Jul;77(13):7539-44
pubmed: 12805454
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4
pubmed: 35436444
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
J Immunol. 2008 Nov 1;181(9):6337-48
pubmed: 18941225
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962